Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)
44.23
-0.36 (-0.80%)
Tarsus Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs in the field of ocular health
The company specializes in the discovery and commercialization of treatments aimed at addressing various eye conditions, with an emphasis on conditions that significantly impact the quality of life. Through its research and development efforts, Tarsus is working to provide patients with effective solutions that enhance vision and overall eye health, leveraging advanced scientific approaches to create novel therapeutic options.
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET.
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), today announced that management will participate in fireside chats at two upcoming investor conferences:
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update.
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update.
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences:
